RS54875B1 - Liofilizovane formulacije fgf-18 - Google Patents
Liofilizovane formulacije fgf-18Info
- Publication number
- RS54875B1 RS54875B1 RS20160453A RSP20160453A RS54875B1 RS 54875 B1 RS54875 B1 RS 54875B1 RS 20160453 A RS20160453 A RS 20160453A RS P20160453 A RSP20160453 A RS P20160453A RS 54875 B1 RS54875 B1 RS 54875B1
- Authority
- RS
- Serbia
- Prior art keywords
- fgf
- freeze
- dried formulations
- formulations
- dried
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Stabilna liofilizovana formulacija koja uključuje FGF-18, fosfatni pufer koji čini da vrednost pH ostane na između 7,0 i 7,5, poloksamer 188 i saharoza.Prijava sadrži još 11 patentnih zahteva.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11170437 | 2011-06-17 | ||
US201161499216P | 2011-06-21 | 2011-06-21 | |
EP12728509.6A EP2720710B1 (en) | 2011-06-17 | 2012-06-15 | Freeze-dried formulations of fgf-18 |
PCT/EP2012/061495 WO2012172072A1 (en) | 2011-06-17 | 2012-06-15 | Freeze-dried formulations of fgf-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
RS54875B1 true RS54875B1 (sr) | 2016-10-31 |
Family
ID=47356563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20160453A RS54875B1 (sr) | 2011-06-17 | 2012-06-15 | Liofilizovane formulacije fgf-18 |
Country Status (31)
Country | Link |
---|---|
US (2) | US9326944B2 (sr) |
EP (2) | EP3056211A1 (sr) |
JP (1) | JP5981538B2 (sr) |
KR (1) | KR102019520B1 (sr) |
CN (2) | CN107715104A (sr) |
AR (1) | AR086956A1 (sr) |
AU (1) | AU2012268987B2 (sr) |
BR (1) | BR112013032400B1 (sr) |
CA (1) | CA2836667C (sr) |
CL (1) | CL2013003618A1 (sr) |
CO (1) | CO6940377A2 (sr) |
CY (1) | CY1117933T1 (sr) |
DK (1) | DK2720710T3 (sr) |
EA (1) | EA024937B1 (sr) |
EC (1) | ECSP14013157A (sr) |
ES (1) | ES2575732T3 (sr) |
HR (1) | HRP20160566T1 (sr) |
HU (1) | HUE028355T2 (sr) |
IL (1) | IL229977A (sr) |
MX (1) | MX338017B (sr) |
MY (1) | MY170630A (sr) |
PE (1) | PE20141265A1 (sr) |
PL (1) | PL2720710T3 (sr) |
PT (1) | PT2720710E (sr) |
RS (1) | RS54875B1 (sr) |
SG (1) | SG195021A1 (sr) |
SI (1) | SI2720710T1 (sr) |
TW (1) | TWI527590B (sr) |
UA (1) | UA113174C2 (sr) |
WO (1) | WO2012172072A1 (sr) |
ZA (1) | ZA201308698B (sr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI527590B (zh) * | 2011-06-17 | 2016-04-01 | 艾瑞斯貿易公司 | Fgf-18之凍乾調配物 |
CA2934638C (en) * | 2013-12-24 | 2022-07-12 | Ares Trading S.A. | Fgf-18 formulation in alginate/collagen hydrogels |
KR20180035911A (ko) * | 2015-08-13 | 2018-04-06 | 메르크 파텐트 게엠베하 | Fgf-18 화합물을 포함하는 조합 조성물 |
DK3706710T3 (da) * | 2017-11-10 | 2024-07-08 | Novartis Ag | Formuleringer med forlænget frigivelse til intraartikulære anvendelser |
CN109836487B (zh) * | 2019-03-01 | 2022-06-17 | 重庆派金生物科技有限公司 | 一种人成纤维细胞生长因子18及其可溶性重组表达方法、制备方法、制剂和应用 |
CN112121150A (zh) * | 2019-06-24 | 2020-12-25 | 杭州生物医药创新研究中心 | 一种成纤维细胞生长因子10冻干粉 |
CN113304063A (zh) * | 2021-04-23 | 2021-08-27 | 四川省恩乐生物工程有限公司 | 一种用于肌肤美容抗衰老的组合物及其制备方法 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5217954A (en) * | 1990-04-04 | 1993-06-08 | Scios Nova Inc. | Formulations for stabilizing fibroblast growth factor |
GB9015824D0 (en) | 1990-07-18 | 1990-09-05 | Erba Carlo Spa | Stable pharmaceutical compositions containing a fibroblast growth factor |
PT2275119E (pt) | 1995-07-27 | 2013-11-21 | Genentech Inc | Formulação de proteína liofilizada isotónica estável |
US20010056066A1 (en) * | 1996-07-26 | 2001-12-27 | Smithkline Beecham Corporation | Method of treating immune cell mediated systemic diseases |
CA2269083C (en) | 1996-10-16 | 2009-06-09 | Zymogenetics, Inc. | Novel fgf homologs |
CN1184673A (zh) * | 1996-12-13 | 1998-06-17 | 中国医科大学 | Fgf粗提多肽生长因子混合物及其提取工艺 |
JP2002527401A (ja) * | 1998-10-13 | 2002-08-27 | カイロン コーポレイション | Fgfの脈管形成的に有効な単位用量および投与方法 |
WO2001039788A2 (en) | 1999-12-02 | 2001-06-07 | Zymogenetics, Inc. | Methods for targeting cells that express fibroblast growth receptor-3 or-2 |
CN1303714A (zh) * | 2000-01-13 | 2001-07-18 | 重庆多泰制药有限公司 | Ii型胶原蛋白口服胃溶制剂 |
AU2001286996A1 (en) * | 2000-08-31 | 2002-03-13 | Chiron Corporation | Stabilized fgf formulations containing reducing agents |
ES2338218T3 (es) * | 2001-07-25 | 2010-05-05 | Facet Biotech Corporation | Formulacion farmacologica liofilizada estable de anticuerpos igg daclizumab. |
DE10204792A1 (de) * | 2002-02-06 | 2003-08-14 | Merck Patent Gmbh | Lyophilisierte Zubereitung enthaltend Immuncytokine |
JP4754823B2 (ja) * | 2002-10-07 | 2011-08-24 | ザイモジェネティクス, インコーポレイテッド | Fgf18の投与方法 |
EP1598074B1 (en) * | 2003-02-28 | 2019-01-02 | Chugai Seiyaku Kabushiki Kaisha | Stabilized protein-containing formulations |
EA012281B1 (ru) * | 2004-06-01 | 2009-08-28 | Арес Трейдинг С.А. | Способ стабилизации белков |
PL2586456T3 (pl) * | 2004-10-29 | 2016-07-29 | Ratiopharm Gmbh | Remodeling i glikopegilacja czynnika wzrostu fibroblastów (FGF) |
US7858341B2 (en) * | 2004-12-10 | 2010-12-28 | Zymogenetics, Inc. | FGF18 production in prokaryotic hosts |
EP1962886B2 (en) * | 2005-12-20 | 2022-02-23 | Bristol-Myers Squibb Company | Stable protein formulations |
JP4729740B2 (ja) * | 2006-01-11 | 2011-07-20 | 独立行政法人産業技術総合研究所 | 受容体特異性を変化させたミュータント増殖因子およびそれを含有する医薬組成物 |
PT1986612E (pt) | 2006-02-07 | 2012-11-06 | Shire Human Genetic Therapies | Composição estável de glucocerebrosidase |
KR101419961B1 (ko) | 2006-08-25 | 2014-07-30 | 아레스 트레이딩 에스.에이. | Fgf-18 로 연골 질환의 치료 |
CA2682147C (en) * | 2007-03-30 | 2017-08-08 | Ambrx, Inc. | Modified fgf-21 polypeptides and their uses |
SI2068909T1 (sl) * | 2007-03-30 | 2012-09-28 | Ambrx Inc | Modificirani fgf-21 polipeptidi in njihova uporaba |
CN101181280B (zh) * | 2007-11-23 | 2010-07-14 | 深圳万乐药业有限公司 | 吡柔比星冻干制剂及其制备方法 |
MY171841A (en) * | 2007-12-21 | 2019-11-04 | Hoffmann La Roche | Antibody formulation |
TWI527590B (zh) * | 2011-06-17 | 2016-04-01 | 艾瑞斯貿易公司 | Fgf-18之凍乾調配物 |
-
2012
- 2012-06-11 TW TW101120864A patent/TWI527590B/zh active
- 2012-06-15 BR BR112013032400-7A patent/BR112013032400B1/pt active IP Right Grant
- 2012-06-15 PE PE2013002832A patent/PE20141265A1/es not_active Application Discontinuation
- 2012-06-15 CN CN201710984784.XA patent/CN107715104A/zh active Pending
- 2012-06-15 MX MX2013014894A patent/MX338017B/es active IP Right Grant
- 2012-06-15 US US14/126,937 patent/US9326944B2/en active Active
- 2012-06-15 CA CA2836667A patent/CA2836667C/en active Active
- 2012-06-15 AU AU2012268987A patent/AU2012268987B2/en active Active
- 2012-06-15 EP EP16161448.2A patent/EP3056211A1/en not_active Withdrawn
- 2012-06-15 HU HUE12728509A patent/HUE028355T2/en unknown
- 2012-06-15 ES ES12728509.6T patent/ES2575732T3/es active Active
- 2012-06-15 AR ARP120102140A patent/AR086956A1/es not_active Application Discontinuation
- 2012-06-15 CN CN201280029683.2A patent/CN103619347A/zh active Pending
- 2012-06-15 RS RS20160453A patent/RS54875B1/sr unknown
- 2012-06-15 SI SI201230600A patent/SI2720710T1/sl unknown
- 2012-06-15 MY MYPI2013702439A patent/MY170630A/en unknown
- 2012-06-15 PL PL12728509.6T patent/PL2720710T3/pl unknown
- 2012-06-15 EP EP12728509.6A patent/EP2720710B1/en active Active
- 2012-06-15 SG SG2013085162A patent/SG195021A1/en unknown
- 2012-06-15 WO PCT/EP2012/061495 patent/WO2012172072A1/en active Application Filing
- 2012-06-15 DK DK12728509.6T patent/DK2720710T3/en active
- 2012-06-15 UA UAA201314452A patent/UA113174C2/uk unknown
- 2012-06-15 JP JP2014515216A patent/JP5981538B2/ja active Active
- 2012-06-15 PT PT127285096T patent/PT2720710E/pt unknown
- 2012-06-15 EA EA201490032A patent/EA024937B1/ru not_active IP Right Cessation
- 2012-06-15 KR KR1020137034615A patent/KR102019520B1/ko active IP Right Grant
-
2013
- 2013-11-20 ZA ZA2013/08698A patent/ZA201308698B/en unknown
- 2013-12-17 IL IL229977A patent/IL229977A/en active IP Right Grant
- 2013-12-17 CL CL2013003618A patent/CL2013003618A1/es unknown
-
2014
- 2014-01-15 CO CO14006968A patent/CO6940377A2/es unknown
- 2014-01-17 EC EC2014013157A patent/ECSP14013157A/es unknown
-
2016
- 2016-04-26 US US15/138,240 patent/US20160228374A1/en not_active Abandoned
- 2016-05-27 HR HRP20160566TT patent/HRP20160566T1/hr unknown
- 2016-06-22 CY CY20161100564T patent/CY1117933T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RS54875B1 (sr) | Liofilizovane formulacije fgf-18 | |
BR112018077266A2 (pt) | composições compreendendo cepas bacterianas | |
BR112018005316A2 (pt) | ?uso de lisina para restabelecer/aumentar a atividade antibacteriana na presença de surfactante pulmonar de antibióticos inibidos desse modo? | |
BR112015009924A2 (pt) | formulações de proteína imunoglobulina de domínio variável duplo estáveis | |
DOP2016000287A (es) | Composiciones y métodos para modular la expresión de ttr y vh | |
MX2019007187A (es) | Composiciones para el cuidado bucal. | |
BR112015025854A2 (pt) | flagelina de roseburia e modulação imunológica | |
MX2019011219A (es) | Administracion rapida y controlada de composiciones con efectos sequito restaurados. | |
BR112014021325A2 (pt) | Formulação farmacêutica líquida e formulação liofilizada | |
BR112015023391A2 (pt) | formulações compreendendo conjugado droga-anticorpo anti-egfr | |
FR2998570B1 (fr) | Peptides, compositions les comprenant et utilisations notamment cosmetiques propigmentantes | |
EP3725321A4 (en) | COMPOSITION WITH A BACTERIUM OF THE GENUS BIFIDOBACTERIUM AS THE ACTIVE SUBSTANCE | |
CO6280406A2 (es) | Polipeptidos anti-microbianos para uso en el tratamiento de transtornos microbianos | |
BR112012029517A2 (pt) | formulações de fragrância, métodos de fabricação e artigos compreendendo as mesmas. | |
AR087745A1 (es) | Composiciones y metodos que comprenden una variante de enzima lipolitica | |
UY34332A (es) | Composiciones y métodos para controlar malezas co mprendiendo un polinucleótido y agente de transfe rencia, y que modulan la fitoeno desaturasa?. | |
BR112012019190A2 (pt) | composições de cuidado oral. | |
EP2994142A4 (en) | Antibiotic and anti-parasitic agents that modulate class ii fructose 1,6-bisphosphate aldolase | |
BR112012019997A2 (pt) | composições de cuidado oral | |
BR112014014410A2 (pt) | composições e métodos que compreendem uma variante de enzima lipolítica | |
BR112016026811A2 (pt) | formulação de anticorpo | |
BR112012023910A2 (pt) | preparações cosméticas ou dermatológicas com um teor de um ou mais derivados de tiazol | |
MX350170B (es) | Composición inmunogénica estable de antígenos de staphylococcus aureus. | |
EP3878445A3 (en) | Acamprosate formulations, methods of using the same, and combinations comprising the same | |
AR092897A1 (es) | Composiciones inmunogenicas |